You are here: Industry Insights > Entresto

News List

Entresto Granted Expanded Indication in Chronic Heart Failure by FDA americanpharmaceuticalreview
February 19, 2021
Novartis announced the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with ...
Financial Report: Novartis contractpharma
November 06, 2020
Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.
Novartis' Entresto racks up a heart failure study win—but it's a mixed one fiercepharma
September 01, 2020
As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indication—but there were some signs of hope.
Novartis Receives Approval for Five Products from Japanese Ministry of Health americanpharmaceuticalreview
July 10, 2020
Novartis Pharma announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved five new treatment options for Japanese patients.
Novartis’s heart failure drug Entresto presents mixed trial results pharmaceutical-technology
September 04, 2019
Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.
Entresto Study Misses Primary Endpoint americanpharmaceuticalreview
August 02, 2019
Novartis announced topline results from the global Phase III PARAGON-HF study, investigating the safety and efficacy of sacubitril/valsartan versus the active comparator valsartan in HFpEF patients.
Cosentyx, Entresto again drive growth at Novartis. But what about the future of Zolgensma? fiercepharma
April 25, 2019
The future of Novartis’ potential blockbuster spinal muscular atrophy gene therapy Zolgensma has come under question, what with a recent child death reported in the company's European trial.
Novartis lifts annual profit outlook as Cosentyx, Entresto lead first-quarter sales growth firstwordpharma
April 25, 2019
Novartis is off to a strong start in 2019 with the Mayzent launch, successful Alcon spin-off and strong operational execution leading us to revise 2019 profit guidance upwards ...
Entresto Awarded Prix Galien Canada Innovative Product Award americanpharmaceuticalreview
December 27, 2018
Novartis heart failure treatment Entresto (sacubitril/valsartan) has been named the winner of the 2018 Prix Galien Canada Innovative Product Award. Entresto was approved in 2015 by Health Canada for....
Entresto tops mainstay ACE inhibitor in heart failure trial pharmaphorum
December 04, 2018
Two years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope of revving up disappointing initial sales, and one of those trials has just delivered positive results.

Previous page 1 2 Next page